Telocytes in human liver fibrosis

Siyi Fu a, b, #, Fei Wang c, #, Yan Cao c, #, Qi Huang d, Junjie Xiao a, b, *, Changqing Yang c, *, Laurentiu M. Popescu e, f

a Regeneration and Ageing Lab and Experimental Center of Life Sciences, School of Life Science, Shanghai University, Shanghai, China
b Innovative Drug Research Center of Shanghai University, Shanghai, China
c Division of Gastroenterology and Hepatology, Digestive Disease Institute, Tongji Hospital, Tongji University School of Medicine, Shanghai, China
d Department of Surgery, Tongji Hospital, Tongji University School of Medicine, Shanghai, China
e Department of Ultrastructural Pathology, Victor Babes National Institute of Pathology, Bucharest, Romania
f Department of Advanced Studies, “Victor Babes” National Institute of Pathology, Bucharest, Romania

Received: December 14, 2014; Accepted: December 23, 2014

Abstract

Liver fibrosis is a wound-healing response which engages a variety of cell types to encapsulate injury. Telocyte (TC), a novel type of interstitial cell, has been identified in a variety of tissues and organs including liver. TCs have been reported to be reduced in fibrotic areas after myocardial infarction, human interstitial wall’s fibrotic remodelling caused either by ulcerative colitis or Crohn’s disease, and skin of systemic sclerosis. However, the role of TCs in human liver fibrosis remains unclear. Liver samples from human liver biopsy were collected. All samples were stained with Masson’s trichrome to determine fibrosis. TCs were identified by several immunofluorescence stainings including double labelling for CD34 and c-kit/CD117, or vimentin, or PDGFR-α, or β. We found that hepatic TCs were significantly decreased by 27%–60% in human liver fibrosis, suggesting that loss of TCs might lead to the altered organization of extracellular matrix and loss the control of fibroblast/myofibroblast activity and favour the genesis of fibrosis. Adding TCs might help to develop effective and targeted antifibrotic therapies for human liver fibrosis.

Keywords: telocytes • liver • fibrosis • CD34 • vimentin • PDGFR-α, β • multiple sclerosis • stellate cells

Introduction

Liver fibrosis, primarily as a result of chronic damages to the liver such as chronic viral hepatitis and fatty liver diseases associated with obesity, is a worldwide burden [1–3]. Liver fibrosis can further progress to cirrhosis, an advanced stage of liver fibrosis, leading to a major cause of morbidity and mortality worldwide [4–6]. This fibrotic response causes all the complications of end-stage liver disease, including portal hypertension, impaired metabolic capacity, synthetic dysfunction and ascites [1]. Unfortunately, currently no standard treatment for liver fibrosis is available and no appropriate antifibrotic drugs has emerged to be effective in human [6–8].

Telocytes (TCs) are a novel type of interstitial cell identified in a variety of tissues and organs including liver [9–19]. Telocytes are completely different from fibroblasts by their distinctive immunophenotypes [9, 10, 20], microRNA profiles [21], gene features [22, 23] and proteome signatures [24]. The striking ultrastructural hallmark of TCs is their very long and thin prolongations called telopodes (Tps) with dilatations (podoms) and thin segments (podomers) [9, 10, 25]. The presence and the conformation of TCs was confirmed by the most advanced microscopic technology available (FIB-SEM Tomography) [26]. By heter- and homocellular junctions or extracellular
vesicles secretion, TCs participate in intercellular signalling, tissue remodelling, renewal and regeneration [9, 10].

Telocytes have been reported to be reduced in myocardial infarction, especially in fibrotic areas [27]. In addition, TCs were progressively lost from the skin, gastric wall, the myocardium and the lung of systemic sclerosis patients [28, 29]. Moreover, the number of TCs is decreased resulting in bowel architectural dysmotility and derangement during human intestinal wall’s fibrotic remodelling affected either by ulcerative colitis or Crohn’s disease [30, 31]. We recently reported the existence of hepatic TCs in the Disse space with a similar density in the four hepatic lobes and their potential role in liver regeneration was emphasized in a mouse model of partial hepatectomy [11, 32]. However, the role of TCs in liver fibrosis remains unclear.

In this study, based on immunofluorescence methods including double labelling for CD34 and c-kit/CD117, or vimentin, or PDGF Receptor-α, or β, we showed that in human liver fibrosis, hepatic TCs were significantly decreased, suggesting that loss of TCs might lead to the altered organization of extracellular matrix and loss the control of fibroblast/myofibroblast activity and favour the genesis of fibrosis.

**Materials and methods**

**Samples**

Human liver fibrosis samples were obtained from liver biopsy examination in Division of Gastroenterology and Hepatology, Digestive Disease Institute.

**Table 1 Clinical characteristics of patients for liver biopsy**

| Case | Age | Gender | Relative liver disease       | Masson* |
|------|-----|--------|-------------------------------|---------|
| 1    | 50  | Male   | Idiopathic portal hypertension | ++      |
| 2    | 40  | Female | Medicamentous liver lesion    | +       |
| 3    | 60  | Male   | Hepatic insufficiency         | ++      |
| 4    | 66  | Female | Autoimmune hepatitis          | +++     |
| 5    | 31  | Male   | Hepatic insufficiency         | +       |
| 6    | 41  | Female | Autoimmune hepatitis          | ++      |
| 7    | 67  | Female | Hepatic lesion                | ++      |
| 8    | 55  | Male   | Alcoholic hepatitis           | -       |
| 9    | 39  | Male   | Hepatic insufficiency         | ++      |
| 10   | 54  | Male   | Cholelithiasis                | -       |
| 11   | 66  | Male   | Hepatic haemangioma           | -       |
| 12   | 47  | Female | Hepatic haemangioma           | -       |
| 13   | 57  | Male   | Cholelithiasis                | -       |

*Trichrome staining for fibrosis.*
Tongji Hospital. As healthy control tissues, samples were from patients who underwent surgery because of neoplastic pathologies. Specimens were collected at least 10 cm from the margin of the tumour. Healthy specimens were carefully chosen to be sure no inflammatory or neoplastic infiltration occur. All samples were divided to healthy or fibrosis specimens based on histopathological examination. All the patients had signed a written informed consent form and the Institutional ethical committees approved this study. The investigation conforms to the principles that are outlined in the Declaration of Helsinki regarding the use of human tissues.

Haematoxylin–eosin and Masson’s trichrome staining
Liver samples were fixed in 4% paraformaldehyde in PBS, and were embedded in paraffin, and sectioned at 5-µm thick. Haematoxylin–eosin and Masson’s trichrome staining were performed with standard procedures to investigate liver histological and fibrotic changes.

Immunofluorescent staining
For investigate the changes in TCs in human liver fibrosis, double immunofluorescence staining for CD34 (red) and PDGFR-α (green) with DAPI (blue) counterstain for nuclei. Telocytes (TCs) are CD34 and PDGFR-α positive. Scale bar = 50 µm. Quantitative analysis of PDGFR-α/CD34 double-positive TCs in sections of liver from controls and liver fibrosis patients. Data are represented as mean ± SD telocyte number per high-power field (hpf). *P < 0.05, compared to controls.

Fig. 2 PDGFR-α/CD34 double-positive telocytes are decreased in liver fibrosis. Double immunofluorescence labelling for CD34 (red) and PDGFR-α (green) with DAPI (blue) counterstain for nuclei. Telocytes (TCs) are CD34 and PDGFR-α positive. Scale bar = 50 µm. Quantitative analysis of PDGFR-α/CD34 double-positive TCs in sections of liver from controls and liver fibrosis patients. Data are represented as mean ± SD telocyte number per high-power field (hpf). *P < 0.05, compared to controls.
and Rabbit polyclonal to PDGF Receptor-alpha (1:100, 3938-1; Epitomics Cambridge, UK) and then sections were exposed for 2 hrs to goat antimouse labelled with Rhodamine (1:200, 115-165-166; Jackson West Grove, Pennsylvania, USA) and donkey anti-rabbit labelled with FITC secondary antibodies (1:200, 711-545-152; Jackson). Finally, sections were stained with DAPI (ProLong™ Gold, Life Technology Carlsbad, CA, USA). The same protocol was used in Rabbit monoclonal to PDGF Receptor-beta (1:100, 1469-1; Epitomics), Rabbit monoclonal to Vimentin (1:100, 2707-1; Epitomics) and Rabbit polyclonal anti-c-kit (1:100, ab5506; Abcam). Each sections was randomly chosen from 20 images (400×) of the central area using confocal laser scanning microscope (LSM 710; Carl Zeiss Microimaging GmbH, Jena Germany) and double immunofluorescent staining was merged using Zen 2011 software (Carl Zeiss Microimaging GmbH). Counting was performed by two independent observers blinded to the sample classification. The density of TCs was expressed as average TCs number in these 20 images.

Statistical analysis

All analyses were evaluated using SPSS 19.0 International Business Machines Corporation, Armonk, NY, USA. Data are expressed as mean ± SD and were analysed by using the Student’s t-test for independent samples. P-values that were less than 0.05 were considered to be statistically significant.

Results

The histopathological changes in all liver samples in this study were determined by haematoxylin–eosin and Masson’s trichrome staining. In healthy liver stage group, hepatocytes had a radial array with clear central veins without occurrence of inflammation, necrosis and fibrosis (Fig. 1). In fibrosis samples, obvious collagen deposition, necro-
sis and inflammation cells’ infiltration could be identified in liver interstitial (Fig. 1). The information for all participants is shown in Table 1. Based on the microscopic examination results obtained from haemat‐

oxygen–eosin and Masson’s trichrome staining, liver specimens were categorized in a healthy stage (n = 4) or a fibrosis phase (n = 9).

Although transmission electron microscopy (TEM) examination is a golden standard for the identification of TCs, immunolabelling, especially double immunolabelling, remains a useful tool for discrimination between TCs and other cells, as well as for semi‐quantitative data analysis. As we and many others have reported, here we used four different double labelling immunofluorescence methods to analyse the changes in TCs in human liver fibrosis, including double labelling for CD34 and PDGFR-α, CD34 and PDGFR-β, CD34 and vimentin, and CD34 and c-kit/CD117. Quantitative analysis of Figure 2 based on CD34 and PDGFR-α double labelling showed a significant reduction in the number of TCs in the fibrotic liver. In agreement with the results based on CD34 and PDGFR-α double labelling, Figures 3–5 also indicated that the number of TCs were severely reduced in liver fibrosis determined by CD34 and PDGFR-β, CD34 and vimentin, and CD34 and c-kit/CD117 double labelling.

Discussion

This study reports a novel finding that TCs are reduced in human liver fibrosis, mirroring the recent findings as described in the colonic wall in ulcerative colitis, the terminal ileum of patients affected by small bowel Crohn’s disease, and skins, gastric wall, lung and myocardium in systemic sclerosis [28–31]. Our data indicate that TCs might be involved in the pathological processes of liver fibrosis.
Fibrosis is a wound-healing response which engages a variety of cell types to encapsulate injury [1, 5–8]. Hepatic stellate cells (HSCs) are considered as the primary source of the fibrogenic population in the liver [33]. In addition, other contributions are also appreciated including portal fibroblasts, bone marrow-derived cells, circulating fibrocytes and fibroblasts from epithelial mesenchymal transition [5–8, 33, 34]. There is now unequivocal and mounting evidence that TCs are definitely distinguished from other interstitial cells (mainly Kupffer cells and hepatic stellate cells) in liver by their location, morphology and immunophenotypes [11]. The microRNA signature, differential gene expression and proteomic profiles have been established between TCs and fibroblast [21–23, 35], although these signatures between TCs and HSCs still deserve explored. We here showed that TCs were decreased in liver fibrosis, further supporting that TCs are different from HSCs which is well-known to be increased in liver fibrosis. Our data based on a series of double immunoreactions clearly indicate a potential role of TCs in the genesis of human liver fibrosis. Unfortunately, because of the lack of appropriate liver samples, we could not determine the ultrastructural features of TCs by TEM and this should be acknowledged as a limitation of this study.

It remains to be determined whether the reduction in TCs precede the process of fibrosis or just a consequence of the fibrotic process. However, based on the literature, several relevant and potential roles could be proposed. First, the reduction in TCs in liver could participate in the abnormal 3D organization of the extracellular matrix as they are involved in intercellular signalling via

![Fig. 5 C-kit/CD34 double-positive telocytes are decreased in liver fibrosis. Double immunofluorescence labelling for CD34 (red) and c-kit (green) with DAPI (blue) counterstain for nuclei. Telocytes (TCs) are CD34 and c-kit positive. Scale bar = 50 μm. Quantitative analysis of C-kit/CD34 double-positive TCs in sections of liver from controls and liver fibrosis patients. Data are represented as mean ± SD telocyte number per high-power field (hpf). *P < 0.05, compared to controls.](image)
either cell-to-cell contacts or shedding microvesicles or exosomes or paracrine secretion including microRNAs [36]. By this, TCs might be able to control the activity of HSCs. Second, the disappearance of TCs might impair hepatocytes and stem cells mediated liver regeneration. Indeed, in recent studies, we have shown that TCs had a close spatial relationships with hepatic putative stem (progenitor) cells and TCs might influence proliferation of hepatocytes and/or the activation of hepatic stem (progenitor) cells [32]. The reduction in TCs might contribute to the depletion of stem cell niches or proliferation of hepatocytes and impair liver regeneration and repair in human liver fibrosis. Further studies will be needed to reveal the functional relationship between TCs and hepatocytes/human liver stem cells. In addition, the therapeutic utility of TCs transplantation for the treatment of liver fibrosis requires further investigation.

In conclusion, this study firstly demonstrated the decrease in TCs in human liver fibrosis based on a series of double immunoreactions. Considering the fact that intramyocardial transplantation of cardiac TCs could decreases MI and improves post-infarcted cardiac function [37], adding TCs might help develop effective and targeted antifibrotic therapies that will modify the natural history of chronic fibrosing disease.

Acknowledgements

This work was supported by the grants from National Natural Science Foundation of China (81200169 to J. Xiao; 81070343 and 81370559 to C. Yang; 81400635 to F. Wang), Innovation Program of Shanghai Municipal Education Commission (13Y2014 to J. Xiao), Foundation for University Young Teachers by Shanghai Municipal Education Commission (year 2012; to J. Xiao), Innovation fund from Shanghai University (sdcx2012038 to J. Xiao), and Program for the integration of production, teaching and research for University Teachers supported by Shanghai Municipal Education Commission (year 2014, to J. Xiao), Joint Projects in Major Diseases funding from Shanghai Municipal Commission of Health and Family Planning (2014ZYJ80201 to C. Yang), Joint Projects for Novel Frontier Technology in Shanghai Municipal Hospital from Shanghai Municipal Commission of Health and Family Planning (SHDC1204122 to C. Yang), Shanghai Medical Guide Project from Shanghai Science and Technology Committee (14411971500 to F. Wang), grants from Chinese Foundation for Hepatitis Prevention and Control (TQGB20140141 to F. Wang) and funds from Shanghai Innovation Program (1243190102 to C. Yang).

Conflicts of interest

The authors declare there are no conflicts of interest.

References

1. Hernandez-Gue V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011; 6: 425–56.
2. Bonder A, Tanner EB, Afadhil NH. Contemporary assessment of hepatic fibrosis. Clin Liver Dis. 2015; 19: 123–34.
3. Iwaisako K, Taura K, Koyama Y, et al. Strategies to detect hepatic myofibroblasts in liver cirrhosis of different etiologies. Curr Pathobiol Rep. 2014; 2: 209–15.
4. Li LC, Gao J, Li J. Emerging role of HMGBl in fibrotic diseases. J Cell Mol Med. 2014; 18: 2331–9.
5. Grieb G, Bucala R. Telocytes and stem cells in liver fibrosis. Adv Wound Care. 2012; 3: 36–40.
6. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012; 18: 1028–40.
7. Fausther M, Lavoie EG, Dranoff JA. Contribution of myofibroblasts of different origins to liver fibrosis. Curr Pathobiol Rep. 2013; 1: 225–30.
8. Iwaisako K, Jiang C, Zhang M, et al. Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci USA. 2014; 111: E3297–305.
9. Popescu LM, Faussone-Pellegrini MS. Telocytes - a case of serendipity: the winding way from interstitial cells of cajal (icc), via interstitial cajal-like cells (ICLC) to telocytes. J Cell Mol Med. 2010; 14: 729–40.
10. Cretoiu SM, Popescu LM. Telocytes revisited. Biomol Concepts. 2014; 5: 533–69.
11. Xiao J, Wang F, Liu Z, et al. Telocytes in liver: electron microscopic and immunofluorescent evidence. J Cell Mol Med. 2013; 17: 1537–42.
12. Yang Y, Sun W, Wu SM, et al. Telocytes in human heart valves. J Cell Mol Med. 2014; 18: 759–65.
13. Diaz-Flures L, Gutierrez R, Saez FJ, et al. Telocytes in neuromuscular spindles. J Cell Mol Med. 2013; 17: 457–65.
14. Chen X, Zheng Y, Manole CG, et al. Telocytes in human oesophagus. J Cell Mol Med. 2013; 17: 1506–12.
15. Zheng Y, Zhu T, Lin M, et al. Telocytes in the urinary system. J Transl Med. 2012; 10: 188.
16. Ceafalan L, Gherghiceanu M, Popescu LM, et al. Telocytes in human skin—are they involved in skin regeneration? J Cell Mol Med. 2012; 16: 1405–20.
17. Luesma MJ, Gherghiceanu M, Popescu LM. Telocytes and stem cells in limbus and uvea of mouse eye. J Cell Mol Med. 2013; 17: 1016–24.
18. Yang XJ, Yang J, Liu Z, et al. Telocytes damage in endometriosis-affected rat ovi-duct and potential impact on fertility. J Cell Mol Med. 2014; doi: 10.1111/jcm.12427.
19. Sheng J, Shim W, Lu J, et al. Electrophysiology of human cardiac atrial and ventricular telocytes. J Cell Mol Med. 2014; 18: 355–62.
20. Bai YH, Zhou QL, Fu SY, et al. Cardiac telocytes and fibroblasts in primary culture: different morphologies and immunophenotypes. PLoS ONE. 2014; Doi:10.1371/journal.pone.0115991.
21. Cismasiu VB, Radu E, Popescu LM. Mir-193 expression differentiates telocytes from other stromal cells. J Cell Mol Med. 2011; 15: 1071–4.
22. Zheng Y, Zhang M, Qian M, et al. Genetic comparison of mouse lung telocytes with mesenchymal stem cells and fibroblasts. J Cell Mol Med. 2013; 17: 567–77.
23. Zheng M, Sun X, Zhang M, et al. Variations of chromosomes 2 and 3 gene expression profiles among pulmonary telocytes, pulmonary, airway cells, mesenchymal stem cells and lymphocytes. J Cell Mol Med. 2014; 18: 2944–60.
24. Zheng Y, Cretoiu D, Yan G, et al. Comparative proteomic analysis of human lung telocytes with fibroblasts. J Cell Mol Med. 2014; 18: 568–89.
25. Niculite CM, Regalia TM, Gherghiceanu M, et al. Dynamics of telopodes (telocyte prolongations) in cell culture depends on extra-
cellular matrix protein. Mol Cell Biochem. 2015; 398: 157–64.

26. Cretoiu D, Hummel E, Zimmermann H, et al. Human cardiac telocytes: 3D imaging by FIB-SEM tomography. J Cell Mol Med. 2014; 18: 2157–64.

27. Zhao B, Chen S, Liu J, et al. Cardiac telocytes were decreased during myocardial infarction and their therapeutic effects for ischaemic heart in rat. J Cell Mol Med. 2013; 17: 123–33.

28. Manetti M, Guiducci S, Ruffo M, et al. Evidence for progressive reduction and loss of telocytes in the dermal cellular network of systemic sclerosis. J Cell Mol Med. 2013; 17: 482–96.

29. Manetti M, Rosa I, Messerini L, et al. A loss of telocytes accompanies fibrosis of multiple organs in systemic sclerosis. J Cell Mol Med. 2014; 18: 253–62.

30. Milia AF, Ruffo M, Manetti M, et al. Telocytes are reduced during fibrotic remodelling of the colonic wall in ulcerative colitis. J Cell Mol Med. 2015; 19: 62–73.

31. Sun X, Zheng M, Zhang M, et al. Differences in the expression of chromosome 1 genes between lung telocytes and other cells: mesenchymal stem cells, fibroblasts, alveolar type ii cells, airway epithelial cells and lymphocytes. J Cell Mol Med. 2014; 18: 801–10.

32. Cismasii VB, Popescu LM. Telocytes transfer extracellular vesicles loaded with miRNA to stem cells. J Cell Mol Med. 2015; Doi:10.1111/jcmm.12529.

33. Zhao B, Liao Z, Chen S, et al. Intramyocardial transplantation of cardiac telocytes decreases myocardial infarction and improves post-infarcted cardiac function in rats. J Cell Mol Med. 2014; 18: 780–9.